The FDA and Gene Therapy for Duchenne Muscular Dystrophy
JAMA · 2024
DOI: 10.1001/jama.2024.5613 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, 2024. Verfasst von David M Rind. Beteiligte Einrichtung: Institute for Clinical and Economic Review, Harvard Medical School, Boston, Massachusetts. Hauptthemen laut MEDLINE: Genetic Therapy, Muscular Dystrophy, Duchenne, United States Food and Drug Administration. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 8 Literaturangaben.
Abstract (Originalsprache)
This Viewpoint examines the appropriateness of FDA accelerated approval of novel gene therapies to treat boys with Duchenne muscular dystrophy following clinical trials with surrogate outcomes that did not demonstrate net benefits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute for Clinical and Economic Review, Harvard Medical School, Boston, Massachusetts.
Zitieren
APA
Rind, D. M. (2024). The FDA and Gene Therapy for Duchenne Muscular Dystrophy. JAMA. https://doi.org/10.1001/jama.2024.5613
Vancouver
Rind DM. The FDA and Gene Therapy for Duchenne Muscular Dystrophy. JAMA. 2024. doi:10.1001/jama.2024.5613
BibTeX
@article{Rind2024,
author = {Rind, David M},
title = {The FDA and Gene Therapy for Duchenne Muscular Dystrophy},
journal = {JAMA},
year = {2024},
doi = {10.1001/jama.2024.5613}
}
EUVIMED